BRPI0908489A2 - uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengue - Google Patents
uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengueInfo
- Publication number
- BRPI0908489A2 BRPI0908489A2 BRPI0908489-4A BRPI0908489A BRPI0908489A2 BR PI0908489 A2 BRPI0908489 A2 BR PI0908489A2 BR PI0908489 A BRPI0908489 A BR PI0908489A BR PI0908489 A2 BRPI0908489 A2 BR PI0908489A2
- Authority
- BR
- Brazil
- Prior art keywords
- chemical compounds
- dengue virus
- attenuate
- virus infection
- designing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010012310 Dengue fever Diseases 0.000 title abstract 2
- 208000025729 dengue disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 1
- 241000710831 Flavivirus Species 0.000 abstract 1
- 238000000126 in silico method Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000008478 viral entry into host cell Effects 0.000 abstract 1
- 230000017613 viral reproduction Effects 0.000 abstract 1
- 210000002845 virion Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20080028A CU20080028A6 (es) | 2008-02-29 | 2008-02-29 | Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus |
| CU2008-0028 | 2008-02-29 | ||
| PCT/CU2009/000002 WO2009106019A2 (es) | 2008-02-29 | 2009-02-27 | Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0908489A2 true BRPI0908489A2 (pt) | 2018-03-27 |
Family
ID=40972816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908489-4A BRPI0908489A2 (pt) | 2008-02-29 | 2009-02-27 | uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengue |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8722742B2 (pt) |
| EP (1) | EP2258356B1 (pt) |
| JP (1) | JP5400067B2 (pt) |
| CN (1) | CN102006865B (pt) |
| AU (1) | AU2009218960B2 (pt) |
| BR (1) | BRPI0908489A2 (pt) |
| CA (1) | CA2716971C (pt) |
| CU (1) | CU20080028A6 (pt) |
| ES (1) | ES2647506T3 (pt) |
| MX (1) | MX2010009563A (pt) |
| WO (1) | WO2009106019A2 (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012502343A1 (en) | 2007-05-23 | 2013-06-17 | Siga Tech Inc | Antiviral drugs for treatment or prevention of dengue infection |
| CN102731394A (zh) * | 2011-04-12 | 2012-10-17 | 中国科学院上海药物研究所 | 取代的喹啉-2-甲醛-苯腙类化合物及其制备方法和用途 |
| EP2794565B1 (en) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis b antiviral agents |
| CN103183631B (zh) * | 2011-12-28 | 2016-08-24 | 天津市国际生物医药联合研究院 | 靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用 |
| US9732067B2 (en) | 2012-06-20 | 2017-08-15 | University Of Kansas | Compounds and methods for activating the apoptotic arm of the unfolded protein response |
| CA3139033A1 (en) | 2012-08-22 | 2014-02-27 | Cornell University | Methods for inhibiting fascin |
| CA2881057C (en) * | 2012-08-28 | 2020-10-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| CU24188B1 (es) * | 2012-12-27 | 2016-07-29 | Ct De Ingeniería Genética Y Biotecnología | Composición vacunal contra el virus dengue |
| JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| HUE040446T2 (hu) | 2013-05-17 | 2019-03-28 | Janssen Sciences Ireland Uc | Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| WO2015011281A1 (en) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ感染の治療のための併用療法 |
| PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
| WO2015127125A1 (en) | 2014-02-20 | 2015-08-27 | Cornell University | Compounds and methods for inhibiting fascin |
| CU20140026A7 (es) * | 2014-03-03 | 2015-11-27 | Ct De Ingeniería Genética Y Biotecnología Biocubafarma | Péptidos horquilla beta con propiedades antivirales contra el virus dengue |
| CA2949229A1 (en) * | 2014-05-23 | 2015-11-26 | F. Hoffmann-La Roche Ag | Benzene sulfonamide derivatives and their use as rorc modulators |
| CN107405392B (zh) * | 2015-02-09 | 2021-05-18 | 中央研究院 | 用于增强对抗登革病毒的安全性及免疫力的抗原表位替换的疫苗 |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017181141A2 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
| CN110022889B (zh) * | 2016-10-03 | 2024-05-10 | 渥太华医院研究所 | 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法 |
| CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| CN108299280A (zh) * | 2018-01-19 | 2018-07-20 | 天津国际生物医药联合研究院 | 对混合谱系白血病关键蛋白具有抑制作用的靛红-5-磺酰胺类抑制剂 |
| SG11202007097QA (en) | 2018-03-14 | 2020-08-28 | Janssen Sciences Ireland Unlimited Co | Capsid assembly modulator dosing regimen |
| US11731964B2 (en) | 2018-04-12 | 2023-08-22 | Purdue Research Foundation | Benzamide antibacterial agents |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
| CN111346079B (zh) * | 2020-02-24 | 2023-06-20 | 南方医科大学 | 细菌dna促旋酶抑制剂brd7716作为治疗和/或预防登革病毒感染的药物及其制药用途 |
| EP4157263A4 (en) * | 2020-05-26 | 2024-09-11 | The Regents Of The University Of Michigan | Mitochondrial targeting compounds for the treatment of associated diseases |
| WO2023158708A1 (en) * | 2022-02-16 | 2023-08-24 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22683A1 (es) * | 1997-01-15 | 2001-07-20 | Inst De Medicina Tropical Pedro Kouri | Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos |
| CU23245A1 (es) * | 2001-07-16 | 2007-10-17 | Inst De Medicina Tropical Pedr | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS |
| WO2005002501A2 (en) | 2003-04-22 | 2005-01-13 | Children's Medical Center Corporation | Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| CU23632A1 (es) * | 2006-04-28 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales. |
| MX2010002656A (es) * | 2007-09-07 | 2010-05-20 | Mevlabs Inc | Formulaciones y dispositivos para suministro de compuestos a artropodos y microorganismos dentro de artropodos. |
-
2008
- 2008-02-29 CU CU20080028A patent/CU20080028A6/es unknown
-
2009
- 2009-02-27 CN CN200980113787XA patent/CN102006865B/zh not_active Expired - Fee Related
- 2009-02-27 CA CA2716971A patent/CA2716971C/en not_active Expired - Fee Related
- 2009-02-27 WO PCT/CU2009/000002 patent/WO2009106019A2/es not_active Ceased
- 2009-02-27 JP JP2010547941A patent/JP5400067B2/ja not_active Expired - Fee Related
- 2009-02-27 ES ES09714439.8T patent/ES2647506T3/es active Active
- 2009-02-27 EP EP09714439.8A patent/EP2258356B1/en active Active
- 2009-02-27 AU AU2009218960A patent/AU2009218960B2/en not_active Ceased
- 2009-02-27 US US12/919,416 patent/US8722742B2/en not_active Expired - Fee Related
- 2009-02-27 MX MX2010009563A patent/MX2010009563A/es active IP Right Grant
- 2009-02-27 BR BRPI0908489-4A patent/BRPI0908489A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009218960A1 (en) | 2009-09-03 |
| CA2716971C (en) | 2016-05-10 |
| MX2010009563A (es) | 2010-09-24 |
| US20110065686A1 (en) | 2011-03-17 |
| AU2009218960B2 (en) | 2013-06-27 |
| US8722742B2 (en) | 2014-05-13 |
| JP2011513250A (ja) | 2011-04-28 |
| CU20080028A6 (es) | 2011-02-24 |
| JP5400067B2 (ja) | 2014-01-29 |
| WO2009106019A3 (es) | 2010-01-28 |
| CN102006865B (zh) | 2013-04-24 |
| EP2258356A2 (en) | 2010-12-08 |
| WO2009106019A2 (es) | 2009-09-03 |
| EP2258356B1 (en) | 2017-09-27 |
| CN102006865A (zh) | 2011-04-06 |
| ES2647506T3 (es) | 2017-12-21 |
| CA2716971A1 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009106019A3 (es) | Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus | |
| CL2013003360A1 (es) | “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct | |
| CL2012001176A1 (es) | Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. | |
| MY202109A (en) | Viral replication inhibitors | |
| MX374333B (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina. | |
| UY34983A (es) | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas | |
| NO20075491L (no) | Fremgangsmate for a behandle infeksjonssykdom-forverret astma | |
| WO2008021936A3 (en) | Hepatitis c virus inhibitors | |
| BRPI1013394A2 (pt) | "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c." | |
| WO2010030538A3 (en) | Compounds for the treatment of hepatitis c | |
| EA201001275A1 (ru) | Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с | |
| ECSP066794A (es) | Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| NO20090453L (no) | Hepatitt C Virusinhibitorer | |
| WO2008086042A3 (en) | Preventing infection by a measles or respiratory syncytial virus | |
| MY194294A (en) | Novel viral replication inhibitors | |
| WO2010021717A3 (en) | Hcv protease inhibitors | |
| CL2009001298A1 (es) | Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4. | |
| WO2007041487A3 (en) | Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family | |
| EA201000277A1 (ru) | Соединения для лечения гепатита с | |
| WO2010055164A3 (en) | Isoquinolone derivatives as inhibitors of plavivirus replication | |
| CL2015001319A1 (es) | Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos. | |
| BR112015007879A2 (pt) | inibidores do vírus da hepatite c | |
| AR053913A1 (es) | Cepa atenuada de dengue serotipo 1 | |
| EA200900780A1 (ru) | Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства | |
| WO2013012835A3 (en) | Sirna useful in the treatment of flavivirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001 |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2555 DE 2019-12-24 |